Dan Young works with clients across a broad range of technology areas to develop and implement IP strategies that are aligned with their business goals through portfolio management, patent prosecution, due diligence support and third-party IP evaluations, focusing primarily in the areas of cell-based therapies, nucleic acid-based therapies, immuno-oncology approaches, antibodies, vaccines, gene therapies, genomics and bioinformatics, biomedical devices, and rare disease therapies.
Speaking In
3:00 PM - 4:00 PM
Tuesday, June 6